AT26863B - Process for preparing concentrated solutions of thiosinamine. - Google Patents

Process for preparing concentrated solutions of thiosinamine.

Info

Publication number
AT26863B
AT26863B AT26863DA AT26863B AT 26863 B AT26863 B AT 26863B AT 26863D A AT26863D A AT 26863DA AT 26863 B AT26863 B AT 26863B
Authority
AT
Austria
Prior art keywords
thiosinamine
concentrated solutions
preparing concentrated
water
solutions
Prior art date
Application number
Other languages
German (de)
Original Assignee
Merck Ag E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1904163804D external-priority patent/DE163804C/de
Application filed by Merck Ag E filed Critical Merck Ag E
Application granted granted Critical
Publication of AT26863B publication Critical patent/AT26863B/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

   <Desc/Clms Page number 1> 
 



  Verfahren zur Darstellung konzentrierter   Lösungen   von Thiosinamin. 



   In der Literatur findet sich überall die Angabe, dass   das Thiosinamin   leicht löslich in Wasser sei. In dieser Allgemeinheit ist aber die Behauptung nicht zutreffend, denn nur in heissem Wasser löst sich Thiosinamin in grossen Mengen auf, während es beim Erkalten fast quantitativ wieder auskristallisiert, da es in kaltem Wasser sehr schwer löslich ist. 



  Dies macht sich bei der Verwendung des Präparates zu subkutanen Injektionen als Übelstand geltend. Ilebra hat aus diesem Grunde eine 15%ige alkoholische Lösung vorgeschlagen. Die Injektionen mit dieser Lösung sind aber so schmerzhaft, dass eine langer ausgedehnte Behandlung, wie sie fast immer erforderlich ist, vollständig ausgeschlossen 
 EMI1.1 
   Losung in warmem Wasser   und Glyzerin. Sie verursacht keine so grossen Schmerzen bei der Einspritzung, hat aber den   Nachteil, dass sich   nach kurzem Stehen wieder Thiosinamin aus ihr ausscheidet, so   d.itss man für eine neue Injektion   wieder erst erwärmen muss.

   Dies   öftere   Erwärmen ist aber dem Thiosinamin nachteilig, indem dasselbe dadurch partiell zersetzt wird, wie aus dem starken Allylgeruch hervorgeht, welchen solche mehrfach erwärmte Lösungen zeigen. Dementsprechend ist auch von verschiedenen Seiten,   insbcsonder ;-   
 EMI1.2 
   gar   uicht schmerzhaft. Sie entspricht also auf das vollkommenste den Anforderungen der Praxis. 



   Ausserdem wirkt aber das salizylsaure Natron noch direkt schmerzstillend, so dass durch seine Anwendung ein doppelter Vorteil erreicht wird. 



   Die so hergestellten Lösungen sollen sterilisiert in zugeschmolzenen Gläschen in den   Hände) gebracht werden.   



   Beispiel 1 : 1 Molekül Thiosinamin und ¸ Molekül salizylsaures Natrium werden in Wasser, Alkohol oder dgl. gelöst und eingedampft. Die zurückbleibende Masse stellt ein weisses kristallinisches Pulver dar, welches in Wasser auch in der   Kälte sehr leicht   
 EMI1.3 
 salizylsauremNatrongibtdasgleicheResultat. 

**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.



   <Desc / Clms Page number 1>
 



  Process for preparing concentrated solutions of thiosinamine.



   In the literature one can find everywhere the statement that thiosinamine is easily soluble in water. In this generality, however, the claim is not correct, because thiosinamine only dissolves in large quantities in hot water, while it crystallizes out again almost quantitatively when it cools, since it is very difficult to dissolve in cold water.



  This makes itself felt as a nuisance when using the preparation for subcutaneous injections. For this reason, Ilebra proposed a 15% alcoholic solution. However, the injections with this solution are so painful that a long, extended treatment, which is almost always necessary, is completely ruled out
 EMI1.1
   Solution in warm water and glycerin. It does not cause that great pain during the injection, but has the disadvantage that thiosinamine is excreted from it again after standing for a short time, so that you have to warm up again for a new injection.

   This frequent heating is disadvantageous for thiosinamine in that it is partially decomposed as a result, as can be seen from the strong allyl odor which such repeatedly heated solutions exhibit. Correspondingly, from different sides, especially special; -
 EMI1.2
   Not at all painful. It therefore corresponds perfectly to the requirements of practice.



   In addition, however, the salicylic acid soda has a direct analgesic effect, so that its use has a double benefit.



   The solutions produced in this way should be sterilized and brought into the hands in sealed vials.



   Example 1: 1 molecule of thiosinamine and ¸ molecule of sodium salicylate are dissolved in water, alcohol or the like and evaporated. The remaining mass is a white crystalline powder, which is very light in water even in the cold
 EMI1.3
 Sodium salicylic acid gives the same result.

** WARNING ** End of DESC field may overlap beginning of CLMS **.

 

Claims (1)

PATENT-ANSPRUCH : EMI1.4 **WARNUNG** Ende CLMS Feld Kannt Anfang DESC uberlappen**. PATENT CLAIM: EMI1.4 ** WARNING ** End of CLMS field may overlap beginning of DESC **.
AT26863D 1904-12-12 1905-09-06 Process for preparing concentrated solutions of thiosinamine. AT26863B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1904163804D DE163804C (en) 1904-12-12

Publications (1)

Publication Number Publication Date
AT26863B true AT26863B (en) 1906-12-27

Family

ID=5683856

Family Applications (1)

Application Number Title Priority Date Filing Date
AT26863D AT26863B (en) 1904-12-12 1905-09-06 Process for preparing concentrated solutions of thiosinamine.

Country Status (1)

Country Link
AT (1) AT26863B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005006950A1 (en) * 2005-02-16 2006-08-24 Nicolay, Stephan, Dipl.-Ing. Transparent permanent/temporary roof for halls/arenas, using hollow chamber plate modules, has fasteners and carrier profiles to lock them together with rods at the carriers inserted into the hollow chambers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005006950A1 (en) * 2005-02-16 2006-08-24 Nicolay, Stephan, Dipl.-Ing. Transparent permanent/temporary roof for halls/arenas, using hollow chamber plate modules, has fasteners and carrier profiles to lock them together with rods at the carriers inserted into the hollow chambers

Similar Documents

Publication Publication Date Title
AT26863B (en) Process for preparing concentrated solutions of thiosinamine.
DE907769C (en) Process for the preparation of a gel-like product from lower alcohols
DE163804C (en)
DE743177C (en) Preparations for washing and caring for living hair
DE631176C (en) Process for the preparation of aqueous solutions of medicines
CH241111A (en) Process for the production of an easily soluble, durable product containing calcium and the gluconic acid residue.
DE663512C (en) Process for increasing the solubility of salicylic acid in fats or fatty oils
DE556368C (en) Process for the preparation of readily soluble sodium salts of acylaminophenolar acids
DE215789C (en)
AT85032B (en) Process for the preparation of an antiluetic.
DE588879C (en) Process for the production of hardenable condensation products of a protein-like type based on urea-formaldehyde
AT138509B (en) Process for the production of permanently stable, concentrated calcium solutions that can also be injected intramuscularly without tissue irritation.
DE193199C (en)
AT108116B (en) Process for the solidification of liquids.
DE639124C (en) Process for the preparation of oil-soluble bismuth salts of organic acids
CH181733A (en) Process for the preparation of a compound of 1-phenyl-2,3-dimethyl-4-isopropyl-5-pyrazolone with B-bromoallyl-isopropylbarbituric acid.
CH187249A (en) Process for the preparation of an oil-soluble bismuth salt.
AT154137B (en) Process for the preparation of double compounds of N.N-disubstituted amides of 3,5-dimethyl-isoxazolearboxylic acid- (4).
AT92089B (en) Process for the production of solid formaldehyde solutions.
AT121328B (en) Method of obtaining the anterior pituitary hormone.
AT81069B (en) Process for the preservation of extracts from drugs Processes for the preservation of extracts from drugs. en.
AT267053B (en) Process for the preparation of the new chloramphenicol succinic acid ester salt of pyrrolidinomethyl-tetracycline
AT52827B (en) Process for the preparation of CC dialkylthiobarbituric acids.
AT142893B (en) Process for the production of condensation products from urea and formaldehyde.
DE469395C (en) Process for the preparation of durable solutions of alkali salts of substituted barbituric acids